# Nuclide record nct06247995 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06247995/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06247995", "NCT06247995" ;
  schema:name "A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor."@en ;
  schema:alternateName "NeoB-Cap1"@en ;
  schema:description "A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06247995/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06247995> ;
  nuclide:status "active" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:drugs <https://nuclide.cc/drugs/capecitabine/> ;
  nuclide:companies <https://nuclide.cc/companies/advanced-accelerator-applications/> .